一场与菌株“斗脾气”的慢跑

Core Insights - The article highlights the innovative achievements of a research team led by Professor Wei Dongzhi at East China University of Science and Technology, particularly in the synthesis of squalene, a high-value compound used in vaccines, pharmaceuticals, and cosmetics [1][3] Group 1: Technological Innovations - The team developed a "multi-enzyme cooperative catalysis" system that allows for the efficient synthesis of squalene from renewable resources like corn and straw, significantly reducing environmental impact compared to traditional methods [3][4] - The fermentation cycle for squalene production was reduced from 10 days to 5 days through continuous experimentation and optimization [1][4] - The innovative approach of "multi-organelle engineering" was introduced, allowing enzymes to self-assemble within cellular compartments, enhancing catalytic efficiency [4][5] Group 2: Industry Impact - The successful large-scale production of squalene has been certified by both the U.S. FDA and China's National Medical Products Administration, making it the world's only pharmaceutical-grade squalene produced via microbial synthesis [4][5] - The advancements in squalene production have opened pathways for the biomanufacturing of thousands of terpene-based fine chemicals, injecting strong momentum into the industry [4][5] Group 3: Research Philosophy and Collaboration - The research institute emphasizes an integrated approach to research and development, breaking down traditional silos and fostering collaboration across various stages of production [5][6] - The philosophy of "organized research" has been a cornerstone of the team's strategy, focusing on solving industrial problems rather than merely producing academic papers [5][6] - The team believes that the next five years will be crucial for China's transition from a major player to a leader in biomanufacturing, with core technological breakthroughs being essential for this development [6]